NKGen Biotech to Present on Troculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy Forum

ConferencetroculeucelNeutral

AI Analysis

Summary

NKGen Biotech announced that CEO Paul Y. Song will present on troculeucel, the company's lead NK cell therapeutic program for neurodegenerative diseases, at the 4th Great Bay Cell and Gene Therapy Forum in Guangzhou, China on September 22-23, 2026.

Importance:2/10

Sentiment:

0.00

cell therapyNK cell therapeuticsautologousallogeneicconference presentationneurodegenerative diseases

Related Companies

$NKGN

Read the original article

Published by GlobeNewswire Clinical Studies on September 15, 2026 12:05 PM

Read Original